Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELEVATE-TN: Acalabrutinib with or without Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL
NCT02475681Phase 3Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Jun 2015
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by Acerta Pharma. Started Jun 2015; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02475681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02475681.